Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the European biotechnology company focused on gene therapies for age-related diseases, has reported that positive safety and efficacy signals from its SLAB trial have been maintained three months after the initial dosing period, with no adverse events observed.
The SLAB (Sarcopenia and Longevity in Aged Beagles) trial is evaluating Genflow's proprietary SIRT6 centenarian gene therapy in aged dogs, targeting sarcopenia, the age-related loss of muscle mass and strength that also affects humans.
The company said improvements across multiple independent endpoints remained consistent with earlier observations reported in February 2026, while control animals continued to show expected age-related decline.
The therapy targets SIRT6, a gene associated with longevity that is found to be more active in centenarians, and is delivered via gene therapy to restore or enhance its function in ageing subjects.
The trial is ongoing, with all animals continuing to be monitored, and completion is anticipated at the end of July 2026.
Additional analyses, including methylation clock assessment, a method of estimating biological age at the cellular level, and muscle histology, the microscopic examination of tissue structure, are in progress and are expected to provide further mechanistic insight into the therapy's effects.
Chief executive Eric Leire said the follow-up data extended the company's understanding beyond initial efficacy and into persistence of effect.
"The consistency of improvements across multiple functional endpoints, together with the continued absence of safety concerns, strengthens our confidence that SIRT6 gene therapy is delivering a sustained biological impact," he said.
Genflow said it was engaging with prospective partners in the animal health sector to explore licensing, co-development and commercialisation opportunities for its SIRT6 platform.